TGM2 and breast cancer: Mikaelian et al. reported that genetic and pharmacologic inhibition of mTORC1 promoted EMT in breast cancer cell lines [47]; this result is consistent with TGM2-induced EMT, which could explain the rapamycin resistance of mTORC1-hyperactive cancer cells.